MaxCyte, Inc. Grant Of Options (9167A)
January 24 2020 - 11:31AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9167A
MaxCyte, Inc.
24 January 2020
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Gaithersburg, Maryland - 24 January 2020: MaxCyte (LSE: MXCT,
MXCS), the global clinical-stage cell-based therapies and life
sciences company, announces that on 20 January 2020, a total of
729,200 options of common stock in the Company ("Common Stock")
were granted to PDMRs who are directors or officers of the Company
("Option Grants"). The annual 2020 grants were approved at a Board
Meeting in December 2019, subject to issuance being following
announcement of the Company's recent trading update ("Trading
Update"). Details of the Option Grants are given below:
Option Grants to PDMRs
Doerfler, Doug 390,200
--------
Holtz, Ron 177,600
--------
Thompson, J. Stark 26,900
--------
Mandell, Art 26,900
--------
Erck, Stan 26,900
--------
Brooke, Will 26,900
--------
Johnston, John 26,900
--------
Douglas, Richard 26,900
--------
Total 729,200
--------
Options Grants to PDMRs vest ratably on a monthly basis over 48
months, have an exercise period of 10 years from date of grant, at
which time they will expire, and have an exercise price equal to
the closing price of MaxCyte's stock on 20 January 2020, of 136.00
pence (being the closing share price on the day of the Trading
Update).
The information set out below is provided in accordance with the
requirements of Regulation 19(3) of the EU Market Abuse Regulation
No 596/2014:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Doerfler, Doug
Holtz, Ron
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
Douglas, Richard
--------------------------- ---------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Thompson, J. Stark - Non-executive Chairman
Mandell, Art - Non-executive Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive Director
Johnston, John - Non-executive Director
Douglas, Richard - Non-executive Director
--------------------------- ---------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name MaxCyte, Inc.
--------------------------- ---------------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------
a) Description of the Grant of Options over Shares of Common
financial instrument, Stock
type of instrument
--------------------------- ---------------------------------------------
b) Identification code US57777K1060
--------------------------- ---------------------------------------------
c) Nature of the transactions
Grant of Options to PDMRs
--------------------------- ---------------------------------------------
d) Price(s) and volume(s) Doerfler, Doug - 390,200 at an exercise
price of 136.00 pence
Holtz, Ron - 177,600 at an exercise price
of 136.00 pence
Thompson, J. Stark - 26,900 at an exercise
price of 136.00 pence
Mandell, Art - 26,900 at an exercise price
of 136.00 pence
Erck, Stan - 26,900 at an exercise price
of 136.00 pence
Brooke, Will - 26,900 at an exercise price
of 136.00 pence
Johnston, John - 26,900 at an exercise
price of 136.00 pence
Douglas, Richard - 26,900 at an exercise
price of 136.00 pence
--------------------------- ---------------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
--------------------------- ---------------------------------------------
e) Date of the transactions 20 January 2020
--------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ---------------------------------------------
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. Through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its technology worldwide, including with all of the top ten
global biopharmaceutical companies. The Company now has more than
100 partnered programme licenses in cell therapy with more than 70
licensed for clinical use. The Company has now signed eight
clinical/commercial licenses with leading cell therapy developers
and the potential pre-commercial milestones from these
relationships now exceeds $650 million. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. MaxCyte is also developing novel CARMA
therapies, with its first drug candidate in a Phase I clinical
trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic
platform for autologous cell therapy for the treatment of solid
cancers. MaxCyte has established CARMA as a wholly owned subsidiary
to facilitate independent investment and new partnerships to
advance the CARMA platform. For more information, visit
www.maxcyte.com
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.
Sukaina Virji com
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBIMFTMTTTBLM
(END) Dow Jones Newswires
January 24, 2020 11:31 ET (16:31 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
